EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Exploring the gut-brain-microbiome axis in Alzheimer's disease: Integrating metagenomics, metabolomics, and artificial intelligence for next-generation biomarker discovery

Tolutope Adebimpe Oso, Mohamed Mustaf Ahmed iD, Olalekan John Okesanya iD, Uthman Okikiola Adebayo iD, Khalifat Boluwatife Obadeyi, Zhinya Kawa Othman iD, Don Eliseo Lucero-Prisno

Journal of Alzheimer’s Disease · 2026-02 · 109 (4) · 1542-1557

DOI: 10.1177/13872877251407700 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Alzheimer’s Disease, online erschienen am 29.12.2025. Verfasst von Tolutope Adebimpe Oso und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Laboratory Science, Neuropsychiatric Hospital, Abeokuta, Nigeria. Hauptthemen laut MEDLINE: Alzheimer Disease, Gastrointestinal Microbiome, Metabolomics, Artificial Intelligence. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 140 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD), a progressive neurodegenerative disorder, is increasingly understood as a multifactorial condition influenced by systemic and environmental factors beyond the central nervous system. A growing body of evidence shows that the gut-brain-microbiome axis (GBMA), a complex bidirectional communication network, is involved in neural, endocrine, immune, and metabolic pathways in AD pathogenesis. This narrative review synthesizes emerging insights into the role of gut microbiota dysbiosis in promoting neuroinflammation, amyloid-β aggregation, blood-brain barrier disruption, and cognitive decline. We explored recent advancements in metagenomics and metabolomics for profiling microbial communities and their functional metabolites linked to AD. Alterations in microbe-derived compounds, such as short-chain fatty acids and tryptophan metabolites, influence neurodevelopment, glial activation, and mitochondrial dysfunction. Multi-omics integration, enhanced by artificial intelligence (AI), enables precise biomarker discovery, patient stratification, and the development of personalized therapeutic strategies. Translational opportunities include microbiome-based diagnostics, probiotic therapy, and stratified interventions. However, clinical translation faces challenges such as methodological heterogeneity, inter-individual microbiome variation, data governance issues, and algorithmic bias. We emphasize the need for diverse reference panels, longitudinal multimodal cohorts, and shared AI-ready datasets to enhance the reproducibility and global equity of research. Strategic investment in integrative, ethically governed, and interdisciplinary approaches is essential to unlock the full therapeutic and diagnostic potential of GBMA in AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseGastrointestinal MicrobiomeMetabolomicsArtificial IntelligenceMetagenomicsBrainHumansBiomarkersDysbiosis

Stichwörter der Autor:innen

Alzheimer's diseasebiomarkersdysbiosisgut-brain axismicrobiotaneuroinflammation

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Medical Laboratory Science, Neuropsychiatric Hospital, Abeokuta, Nigeria.
  • Department of Medical Laboratory Science, McPherson University, Seriki Sotayo, Nigeria.
  • Faculty of Medicine and Health Sciences, SIMAD University, Mogadishu, Somalia.
  • School of Global Health, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Faculty of Medicine, Department of Public Health and Maritime Transport, University of Thessaly, Volos, Greece.
  • Department of Medical Laboratory Science, College of Basic Health Sciences, Achievers University, Owo, Nigeria.

ORCID-Profile: Mohamed Mustaf Ahmed, Olalekan John Okesanya, Uthman Okikiola Adebayo, Zhinya Kawa Othman

Zitieren

APA

Oso, T. A., Ahmed, M. M., Okesanya, O. J., Adebayo, U. O., Obadeyi, K. B., Othman, Z. K., & Lucero-Prisno, D. E. (2026). Exploring the gut-brain-microbiome axis in Alzheimer's disease: Integrating metagenomics, metabolomics, and artificial intelligence for next-generation biomarker discovery. Journal of Alzheimer’s Disease, 109(4), 1542-1557. https://doi.org/10.1177/13872877251407700

Vancouver

Oso TA, Ahmed MM, Okesanya OJ, Adebayo UO, Obadeyi KB, Othman ZK, et al. Exploring the gut-brain-microbiome axis in Alzheimer's disease: Integrating metagenomics, metabolomics, and artificial intelligence for next-generation biomarker discovery. Journal of Alzheimer’s Disease. 2026;109(4):1542-1557. doi:10.1177/13872877251407700

BibTeX
@article{Oso2026,
  author = {Oso, Tolutope Adebimpe and Ahmed, Mohamed Mustaf and Okesanya, Olalekan John and Adebayo, Uthman Okikiola and Obadeyi, Khalifat Boluwatife and Othman, Zhinya Kawa and Lucero-Prisno, Don Eliseo},
  title = {Exploring the gut-brain-microbiome axis in Alzheimer's disease: Integrating metagenomics, metabolomics, and artificial intelligence for next-generation biomarker discovery},
  journal = {Journal of Alzheimer’s Disease},
  year = {2026},
  volume = {109},
  number = {4},
  pages = {1542--1557},
  doi = {10.1177/13872877251407700}
}
Kostenlos starten →